ALPA LABORATORIES LTD.

Alpa Laboratories Ltd's board approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board also approved the auditor's report with an unmodified opinion. M/s S. S. Gandhi & Associates and M/s. Sudeep Saxena & Associates were appointed as Internal Auditor and Cost Auditor for the financial year 2026-27, respectively. The meeting, held on May 29, 2026, commenced at 4:00 PM and concluded at 10:00 PM.

Alpa Laboratories Ltd has scheduled a Board of Directors meeting on May 29, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board will also review the auditor's report issued by M/s C.H Padliya & Co., Chartered Accountants. The meeting will be held at the company's registered office at 4:00 P.M.

Alpa Laboratories Ltd, in response to an email dated 8th April 2026, has clarified that there is no price sensitive information that has not been disclosed. The company does not have any future announcements that may impact the price or volume of the scrip.

Alpa Laboratories Ltd has announced the closure of its trading window, which will remain closed from 01st April 2026 till 48 hours after the declaration of the Financial results for the fourth quarter and financial year ending March 31, 2026. This decision is in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) (Amendment) Regulations, 2018, and the company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders.

Alpa Laboratories Ltd. has received disclosures under Regulation 10(6), 29(1), and 29(2) of SEBI (SAST) Regulations, 2011 from Promoter/Promoter Group/immediate relatives of Promoter/Promoter Group. Mr. Vinit Shah, an immediate relative of Promoter/Promoter Group, acquired 21,940 (0.10%) equity shares via inter se transfer (by way of gift) from Bakulesh Chandulal Shah HUF. There is no change in the total shareholding of Promoter and Promoter Group of the Company pre and post transfer of shares.

Alpa Laboratories Ltd has received disclosures under Regulation 10(6), 29(1) and 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations 2011 from Promoter/Promoter Group/ immediate relatives of Promoter/Promoter Group. Mr. Vinit Shah has acquired 0.10% shares via inter se transfer (by way of gift). Bakulesh Chandulal Shah HUF has disclosed disposal of shares via inter se transfer (by way of gift). Despite these transfers, the total shareholding of Promoter and Promoter Group of the Company remains the same.

Alpa Laboratories Ltd. has approved the un-audited standalone and consolidated financial results for the quarter ended on 31st December 2025. The approval came during a Board of Directors meeting held on 11th February 2026. The company has prepared the financial statements in accordance with Indian Accounting Standards (Ind AS) and other accounting principles generally accepted in India.

Alpa Laboratories Limited has approved the un-audited standalone and consolidated financial results for the quarter ended on 31st December, 2025. The approval came during a Board Meeting held on 11th February, 2026. The financial results were reviewed by the independent auditor, C.H. Padliya & Co., and found to be in compliance with the Indian Accounting Standards and other applicable accounting principles.

Alpa Laboratories Ltd. has informed the BSE that their Board of Directors will meet on February 11, 2026, to consider and approve the unaudited financial results for the quarter ended on December 31, 2025. The trading window closure disclosure, made on December 25, 2025, will be applicable for this announcement.

Alpa Laboratories Ltd. has announced the closure of its trading window in accordance with the SEBI (Prohibition of Insider Trading) Regulation, 2015. The closure is effective from 1% January, 2026 until 48 hours after the declaration of the Unaudited Financial Results for the quarter ending December 31, 2025. This decision is in line with the Securities and Exchange Board of India (Prohibition of Insider Trading) (Amendment) Regulations, 2018, and the company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders.